Back to Top Skip to main content

DoD P&T Committee Resources

View and download Formulary Management Documents and/or Executive Summaries from below.

Formulary Management Documents

File Date
Formulary Management for Growth Stimulating Agents (GSAs) 10/15/2018
Formulary Management for Opioid Induced Constipation 10/15/2018
Formulary Management for Pancreatic Enzyme Replacement Therapy 10/15/2018
Formulary Management for the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) 5/21/2018
Formulary Management of Weight Loss Agents 5/21/2018
Formulary Management for Basal Insulin Analogs 11/2/2017
Formulary Management for Ophthalmic-1s: Antihistamine and Dual Acting Antihistamine/Mast Cell Stabilizers 8/18/2017
Formulary Management for Idiopathic Pulmonary Fibrosis 8/18/2017
Formulary Management for Diabetes Drugs 3/20/2017
Formulary Management for Oral Anticoagulants 2/21/2017
Formulary Management for PCSK9 Inhibitors 2/21/2017
Formulary Management for Narcotic Antagonists August 2016 11/28/2016
Formulary Management for Topical Acne and Rosacea Agents August 2016 11/28/2016
Formulary Management for Triptans August 2016 11/28/2016
Formulary Management for Anticonvulsants and Anti Mania Agents 8/2/2016
Formulary Management for Atypical Antipsychotic Agents 8/2/2016
Formulary Management for Emergency Contraceptive Agents 8/2/2016
Formulary Management for Opthalmic Immunomodulatory Agents: Cyclosporine 0.05% Opthalmic Emulsion 5/19/2016
Formulary Management for Oral Contraceptives and Miscellaneous Contraceptives 5/19/2016
Formulary Management for OTC Doxylamine 5/19/2016
Formulary Management for Topical Antifungals for Onychomycosis Subclass 5/19/2016
Formulary Management Table for Oral Contraceptives 5/19/2016
Formulary Management for Gastrointestinal-2 (GI-2) Miscellaneous Drugs 2/17/2016
Formulary Management for Anti-Rheumatic Drugs; Injectable Methtrexate Subclass 2/16/2016
Formulary Management for Attention Deficit/Hyperactivity Disorder Stimulant Agents 2/16/2016
Formulary Management for Oral Isotretinoins for Severe Recalcitrant Nodular Acne 2/16/2016
Formulary Management for Chronic Myelogenous Leukemia 12/14/2015
Formulary Management for Long Acting High Potency Narcotic Analgesics 12/14/2015
Formulary Management for Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2) 12/14/2015
Formulary Management for Hepatitis C Virus Direct Acting Agents 9/2/2015
Formulary Management for Self-Monitoring Blood Glucose Systems (SMBGS) Test Strips 9/2/2015
Formulary Management for Nitric Oxide Agents Used in the Treatment of Pulmonary Arterial Hypertension 7/1/2015
Formulary Management for Prostate Subclass I and II Cancer Drugs 7/1/2015
Formulary Management for Transmucosal Immediate Release Fentanyl Products 7/1/2015
Formulary Management for Multiple Sclerosis Drugs 2/1/2015
Formulary Management for Targeted Immunomodulatory Biologics 12/1/2014
Formulary Management for Inhaled Corticosteroids 9/1/2014
Formulary Management for Inhaled Nasal Allergy Drugs 9/1/2014
Formulary Management for Oral Bisphosphonates 9/1/2014
Formulary Management for Gastrointestinal-1 Drug Class Oral Aminosalixylates (5-ASA) Subclass 7/1/2014
Formulary Management for Inhaled Corticosteroids/Long-Acting Beta Agonists (ICS/LABAs) 7/1/2014

Executive Summaries

File Date
DoD P&T Committee Executive Summary: Ophthalmic-1s: Antihistamine and Dual Acting Antihistamine/Mast Cell Stabilizers 8/22/2017
DoD P&T Committee Executive Summary: Idiopathic Pulmonary Fibrosis 8/22/2017
DoD P&T Committee Executive Summary: Direct-Acting Anticoagulants 5/11/2017
DoD P&T Committee Executive Summary: PCSK9 Inhibitor Subclass 2/21/2017
DoD P&T Committee Executive Summary: Migraine Agents - Triptans 11/28/2016
DoD P&T Committee Executive Summary: Alcohol Deterrents - Narcotic Antagonist 11/28/2016
DoD P&T Committee Executive Summary: Topical Acne and Rosacea Agents 11/28/2016
DoD P&T Committee Executive Summary: Anticonvulsants and Anti Mania Agents 8/1/2016
DoD P&T Committee Executive Summary: Atypical Antipsychotic Agents 8/1/2016
DoD P&T Committee Executive Summary: Emergency Contraceptive Agents 8/1/2016
DoD P&T Committee Executive Summary: Contraceptive Agents 5/19/2016
DoD P&T Committee Executive Summary: Ophthalmic Immunomodulatory Agents Cyclosporine 0.05% Ophthalmic Emulsion (Restasis) 5/19/2016
DoD P&T Committee Executive Summary: Topical Antifungal Drugs for Onychomycosis 5/19/2016
DoD P&T Committee Executive Summary: Chronic Myelogenous Leukemia 12/14/2015
DoD P&T Committee Executive Summary: Extended Release Opioids 12/14/2015
DoD P&T Committee Executive Summary: Glucagon-Like Peptide-1 Receptors Agonist (GLP1RA) 12/14/2015
DoD P&T Committee Executive Summary: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2) 12/14/2015
DoD P&T Committee Executive Summary: Hepatitis C Virus Direct Acting Agents 5/1/2015
DoD P&T Committee Executive Summary: Pulmonary Arterial Hypertension Drugs 2/1/2015
DoD P&T Committee Executive Summary: Prostate Cancer Subclass I/II Drugs Oral Oncology 2/1/2015
DoD P&T Committee Executive Summary: Transmucosal Immediate Release Fentanyl Products 2/1/2015

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.